Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/21725
Title: Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
Authors: 
Mesh: 
Issue Date: 2-Jul-2015
Citation: N. Engl. J. Med..2015 Jul;(373)1:23-34
Abstract: Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab (a cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] checkpoint inhibitor) have been shown to have complementary activity in metastatic melanoma. In this randomized, double-blind, phase 3 study, nivolumab alone or nivolumab plus ipilimumab was compared with ipilimumab alone in patients with metastatic melanoma.
PMID: 26027431
URI: https://hdl.handle.net/20.500.12530/21725
Rights: openAccess
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. General U. Gregorio Marañón > Artículos

Files in This Item:
File Description SizeFormat 
PMC5698905.pdf367.57 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.